• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov7
Oppenheimer and William Blair Analysts Reiterate Buy Rating on Allogene Therapeutics
02:56
Allogene Therapeutics released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 0 (forecast USD 1.82 K), actual EPS USD -0.1864 (forecast USD -0.2224)
00:00
Allogene Therapeutics released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 0, actual EPS USD -0.7
00:00
Oct30
Allogene Therapeutics to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 1.82 K, EPS USD -0.2224
00:09
Oct10
Analyst Cheng covers healthcare industry and focuses on specific stocks
09:46
Aug13
Allogene Therapeutics released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2326 (forecast USD -0.2752)
23:00

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -41.4 M, EPS -0.1864

Aug13
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -50.94 M, EPS -0.2326

May13
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -59.73 M, EPS -0.2773

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
VMAR
0.9557
+151.43%
+0.575
AMCI
13.200
+81.57%
+5.930
SRXH
0.5272
+73.14%
+0.223
RILY
5.820
+56.45%
+2.095
CPAC
10.616
+51.87%
+3.626
EDHL
0.5447
+42.74%
+0.163
ADGM
1.140
+37.11%
+0.306
EEX
4.820
+36.16%
+1.280
PETS
3.890
+35.54%
+1.020
ALDX
5.380
+34.84%
+1.390
View More